Last updated: February 16, 2026
Product Overview:
NDC 51672-4046 corresponds to Xywav, a branded calcium, magnesium, and potassium-based oxybate formulation approved for narcolepsy and cataplexy. It is marketed by Jazz Pharmaceuticals as a medication with an expanded label similar to that of Xyrem but with a different formulation.
Market Size and Penetration
Current Market Landscape:
- Global narcolepsy treatments primarily include sodium oxbate formulations such as Xyrem (sodium oxybate) and Xywav.
- The U.S. narcolepsy drug market was valued at approximately $1.2 billion in 2022, with Xyrem accounting for nearly 70% of sales (IQVIA).
- The remaining market share is split among newer formulations and off-label therapies.
- The approval of Xywav in 2020 expanded treatment options and reduced sodium content, targeting patients with hypertension, edema, or metabolic concerns.
Marketed Indications:
- Narcolepsy with or without cataplexy.
- Idiopathic hypersomnia (pending further approvals).
Market Penetration Factors:
- Xywav benefits from lower sodium content, appealing to patients at risk for cardiovascular problems.
- Physicians favor its safety profile; however, high costs and regulatory restrictions impact adoption.
- Innovative packaging and delivery models contribute to enhanced patient compliance.
Price Analysis and Projection
Historical Pricing Data:
- Xyrem: The wholesale acquisition cost (WAC) in 2022 was approximately $60 per mL.
- Xywav: Launched with a WAC of about $45 per mL in 2020, reflecting a 25% lower price due to formulation differences.
Current Market Pricing (as of early 2023):
- Both drugs are supplied via specialty pharmacies with significant net pricing discounts; the effective out-of-pocket cost for patients can range from $0 to several thousand dollars per year depending on insurance coverage.
- Post-rebate net prices for insurers hover around 50-60% of WAC.
| Price Trends and Projections (2023-2027): |
Year |
Estimated Average Price per mL |
Notes |
| 2023 |
$44 |
Slight decline from initial launch price due to market competition and rebate negotiations. |
| 2024 |
$42 |
Entry of biosimilar or generic oxybate formulations could pressure prices further. |
| 2025 |
$40 |
Potential for tiered discounts driven by increased competition and formulary shifts. |
| 2026 |
$38 |
Larger payer negotiations could further reduce net payer cost. |
| 2027 |
$36 |
Biosimilar entrants could expand market share, further compress prices. |
Note: Prices are in nominal dollars, assuming no significant shifts in regulatory or policy environments.
Factors Influencing Price Dynamics:
- Market Competition: The entry of biosimilar oxybate products or additional formulations could lead to price erosion.
- Regulatory Changes: Policy shifts favoring generic or biosimilar substitution may pressure prices down.
- Market Expansion: Approval for additional indications could expand usage and sustain premium pricing.
Regulatory and Market Risks
-
Patent and Exclusivity:
Jazz Pharmaceuticals holds patents through 2030, but biosimilar competition may emerge earlier, especially in international markets.
-
Pricing Policies:
Canadian and European markets face stricter price controls that may influence U.S. pricing strategies indirectly.
-
Reimbursement Policies:
Continued emphasis on value-based models could reduce average reimbursement levels, affecting net prices.
Key Takeaways
- The U.S. narcolepsy drug market was approximately $1.2 billion in 2022, with Xywav occupying a growing niche due to its lower sodium content.
- Pricing for NDC 51672-4046 (Xywav) remained stable post-launch but is set to decline gradually due to biosimilar competition and market dynamics.
- The estimated average price per mL is expected to decrease from $44 in 2023 to $36 in 2027.
- Market expansion into new indications and international markets could offset downward pricing pressures.
- Regulatory and patent landscapes influence both pricing stability and risk levels.
FAQs
1. How does Xywav's pricing compare to Xyrem?
Xywav's initial WAC was approximately 25% lower than Xyrem's, reflecting its formulation advantages. However, actual net prices depend on rebates and negotiations.
2. What are the major factors driving price declines?
Biosimilar entry, formulary negotiations, and regulatory policies are primary factors promoting price reductions.
3. Will new indications impact pricing?
Potential approval for additional indications like idiopathic hypersomnia could increase demand, possibly supporting steady or higher pricing.
4. What is the expected timeline for biosimilar competition?
Biosimilar oxybate products could enter the U.S. market within 3-5 years, contingent on clinical trial progress and regulatory approvals.
5. How may policy changes affect the market?
Price regulations, especially on specialty drugs, can restrict pricing flexibility and margin potential for manufacturers.
References
- IQVIA. "U.S. Market Data: Prescription Drug Market Overview 2022."
- Jazz Pharmaceuticals. "Xywav Prescribing Information," 2021.
- FDA. "Oxybate Products for Narcolepsy," 2020.
- Pharmaceutical Market Research Reports. "Narcolepsy Treatment Market Trends," 2022.
